MuhamedBaljevicMD

Hematologic Oncology

Physician

Dr. Baljevic is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
3601 21st Ave S
Nashville, TN 37232
Phone+1 615-322-3000

Fax+1 402-552-2512

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2013 - 2016
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2010 - 2013
Weill Cornell Medical College in QatarClass of 2010

PubMed

23 citations
Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.
Meera Mohan, Rajshekhar Chakraborty, Susan Bal, Anoma Nellore, Muhamed Baljevic
British Journal of Haematology. 2023-12-01
96 citations
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.
Natalie S Callander, Muhamed Baljevic, Kehinde Adekola, Larry D Anderson, Erica Campagnaro
Journal of the National Comprehensive Cancer Network. 2022-01-01
1 citations
Long term responders in frontline multiple myeloma-exception vs expectation of the modern era.
Muhamed Baljevic, Douglas W Sborov, Shaji K Kumar
Blood Cancer Journal. 2024-07-17

Abstracts/Posters

Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma
Muhamed Baljevic, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
The Effect of Age and CD34+ Stem Cell Dose on Autologous Hematopoietic Stem Cell Transplantation Outcomes in Multiple Myeloma _ Single Institution Experience
Muhamed Baljevic, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019